S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
GELS$0.4968+1.47%
Gelteq Ltd
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: AUExchange: Nasdaq
Mkt Cap:$5.56M
Float & O/S:
Inst Own:
DilutionScan read 15 of Gelteq Ltd's SEC filings and found 1 warrant series, 9 convertibles, 1 equity line, 1 S-1 registration and 4 completed offerings on file for GELS. The latest dilution event on file is an offering on Jun 26, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
GELS
Going-concern warning and exhausted cash
Snapshot
Gelteq is a micro-cap biotech in a severe liquidity crisis. It generated just $116K in FY 2025 revenue against a $4.7M net loss, burning through $4.3M in free cash flow.
What's Happening Right Now
- : The company filed its earnings with a six-month delay, reporting a working capital deficit and cash under $10,000, with auditors preparing the statements on a going concern basis.
- : Gelteq announced that human clinical trials are set to begin in July 2026 and secured a $3.5 million strategic debt facility to fund operations.
- : Management called a special shareholder meeting to approve issuing shares above the Nasdaq 19.9% limit to facilitate the conversion of recent debt financing.
Raise routes on file: effective S-1 + active equity line · latest dilution event 130 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jun 26, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible Promissory Note #1 (Initial Note, May 7, 2026)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible Promissory Note #2 (Second Tranche Note, June 26, 2026)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
May 2023 Convertible Notes (, discount)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
February 2024 Convertible Notes
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
May 2024 Convertible Notes (, discount)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Equity line
Issued 2025
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your GELS trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
